Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Global Regulators Focus On Promoting Reliance During Public Health Emergencies

E-Labeling, Environmental Risk Assessment High On Agenda

Executive Summary

Agencies participating in the International Pharmaceutical Regulators Programme discussed priorities, welcomed the UK as the newest IPRP member and endorsed a new regulatory tool to support the assessment of quality-related information in marketing applications.

You may also be interested in...

Environmental Criteria in Medicines Tendering Set To Increase

Environmental criteria in tendering could lead to short term cost increases but long-term savings for pharmaceutical companies.

UK Regulator Eyes Expedited Process For Securing Full ICH Membership

The UK is on a mission to re-join the International Council for Harmonisation as a fully active member with voting rights.

Lean On Me: WHO Offers Practical Advice On Regulatory Reliance

A new draft document by the World Health Organization explains how regulatory authorities can leverage the work done by others to gain efficiencies and avoid duplication.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts